BIOCRYST PHARMACEUTICALS, INC. (BCRX) Total liabilities 2016–2025
BIOCRYST PHARMACEUTICALS, INC. (BCRX) total liabilities at each fiscal year-end, per SEC filings.
$633.3MFY2025 · since FY2016: $88.3M → $633.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $633.3M | -34.5% |
| FY2024 | $966.4M | -0.6% |
| FY2023 | $972.5M | +15.1% |
| FY2022 | $844.6M | +21.5% |
| FY2021 | $695.1M | +96.4% |
| FY2020 | $354.0M | +158.3% |
| FY2019 | $137.0M | +40.4% |
| FY2018 | $97.6M | +3.3% |
| FY2017 | $94.5M | +7.1% |
| FY2016 | $88.3M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice